4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off

2 months ago 22

Prosper Junior Bakiny, The Motley Fool

Sat, Apr 26, 2025, 3:05 PM 5 min read

It's ever a bully clip to bargain coagulated dividend stocks, but considering the challenging economical environment, present mightiness beryllium a peculiarly opportune time. Dividend-paying companies thin to person beardown underlying operations and are mostly much resilient than their non-dividend-paying counterparts. With a volatile equity marketplace and a imaginable recession looming owed to the interaction of tariffs, dividend stocks tin assistance fortify immoderate portfolio.

With that arsenic a backdrop, let's see 4 fantabulous income stocks that investors tin bargain amid the existent sell-off: AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), Bristol Myers Squibb (NYSE: BMY), and Zoetis (NYSE: ZTS).

Where to put $1,000 close now? Our expert squad conscionable revealed what they judge are the 10 champion stocks to bargain close now. Continue »

AbbVie is simply a starring drugmaker champion known for its enactment successful immunology. The institution has encountered immoderate issues successful caller years, including a large patent cliff and a objective setback for a merchandise galore thought looked promising. However, AbbVie's fiscal results stay solid. Thanks to medicines specified arsenic Skyrizi and Rinvoq, which dainty a scope of autoimmune conditions, AbbVie's gross is moving successful the close direction.

AbbVie's absorption has agelong predicted that Skyrizi and Rinvoq volition assistance thrust top-line maturation good into the 2030s. As grounds of these medicines' unthinkable performance, AbbVie precocious accrued its 2027 guidance for the duo by $4 cardinal to much than $31 billion. The institution does person different weapons successful its arsenal.

Newer products, similar migraine attraction Qulipta, should person a meaningful impact, portion older franchises, specified arsenic Botox, proceed to marque coagulated contributions. AbbVie besides has a heavy pipeline of candidates.

Lastly, the company's dividend programme looks impressive, considering it has had 53 consecutive years of payout increases (including its clip arsenic portion of Abbott Laboratories) -- and there's nary crushed to deliberation that won't continue. AbbVie's guardant output of 3.9% is good supra the S&P 500's mean of 1.3%.

Amgen's shares fell precocious past twelvemonth erstwhile its starring value nonaccomplishment candidate, MariTide, did not execute arsenic good arsenic expected successful a signifier 2 objective trial. However, MariTide inactive looks apt to beryllium a somewhat palmy value absorption medicine, and Amgen has overmuch much than conscionable that going its way. The company's lineup features galore salient products, including implicit 10 blockbuster drugs. Several of its medicines are expected to beryllium cardinal maturation drivers for the foreseeable future.